M&A Deal Summary |
|
---|---|
Date | 2013-02-27 |
Target | Enaleni Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Cipla |
Deal Type | Add-on Acquisition |
Deal Value | 4.5B ZAR |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1935 |
Sector | Life Science |
Employees | 25,672 |
Revenue | 254.5B INR (2024) |
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. Cipla was founded in 1935 and is based in Mumbai, India.
DEAL STATS | # |
---|---|
Overall | 1 of 6 |
Sector (Life Science) | 1 of 4 |
Type (Add-on Acquisition) | 1 of 4 |
Country (South Africa) | 1 of 2 |
Year (2013) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-09-03 |
InvaGen Pharmaceuticals
Hauppauge, New York, United States InvaGen Pharmaceuticals, Inc. is a generic pharmaceutical company in the US. InvaGen is engaged in development, manufacturing, marketing and distributing of generic pharmaceuticals with focus on wide range of therapeutic areas including, cardiovascular, anti-infective, CNS, anti-inflammatory, anti-diabetic and anti-depressants. |
Buy | - |